Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …

Despite significant progress in the development of treatment options, melanoma remains a
leading cause of death due to skin cancer. Advances in our understanding of the genetic …

The global incidence of malignant melanoma, the leading cause of skin cancer death, has
steadily increased in recent years. Surgical excision is the treatment of choice for early-stage …

In melanoma, the induction of lymphatic growth (lymphangiogenesis) has long been
correlated with metastasis and poor prognosis, but we recently showed it can synergistically …

Background For patients with sentinel lymph node (SLN)‐positive cutaneous melanoma, the
Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease …

Introduction This systematic scoping review compares the toxicities experienced by patients
receiving immune checkpoint inhibitors (ICIs) or targeted therapy (TT) for stage III (resected …

The growing repertoire of approved immune-checkpoint inhibitors and targeted therapy has
revolutionized the adjuvant treatment of melanoma. While the treatment of primary …

Background Patients with sentinel lymph node-positive (SLN+) melanoma are increasingly
undergoing active nodal surveillance over completion lymph node dissection (CLND) since …

Introduction Adjuvant therapy trials required completion lymph node dissection (CLND) for
sentinel lymph node (SLN)-positive melanoma prior to systemic treatment, but nodal …

Pump-probe microscopy of melanin in tumors has been proposed to improve diagnosis of
malignant melanoma, based on the hypothesis that aggressive cancers disaggregate …